Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-06-27 00:08 UTC (UTC+2h)
 

Potvin C in the EU [Two-Stage / GS Designs]

posted by Helmut Homepage - Vienna, Austria, 2013-04-16 15:40  - Posting: # 10424
Views: 13,887

Dear all,

new experiences from an ongoing MRP. Two studies (first one in two groups due to logistic reasons), Method C (!), all metrics in both studies passed in stage 1 (>80% power in the interim, no α-adjustment = 90% CIs).

Studies’ models in stage 1:
  1. Fixed:  sequence, period, treatment, group, group × treatment
    Random: subject(sequence)

  2. Fixed:  sequence, period, treatment
    Random: subject(sequence)
Accepted by Germany (RMS); no comments from Austria, Denmark, Sweden, and The Netherlands. Spain:

“Statistical analysis should be GLM. Please justify. Please provide the NOL.”

OK, I will repeat the analyses with all fixed effects (sigh; identical CIs…). ;-)
BTW, does anybody know what “NOL” means?

P.S.: All metrics would have passed with αadj 0.0294 (Method B) as well. I did not report these results and interestingly surprisingly was not asked for them.

[image]All the best,
Helmut Schütz 
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,007 Posts in 3,644 Threads, 1,043 registered users;
15 users online (0 registered, 15 guests).

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed